All News

Patients with early-stage breast cancer are advised to ask their provider what the least invasive treatment option is available to them that gives them both a great cure rate and a much better quality of life.

After going public with my cancer diagnosis, I was met with an onslaught of “grief tourists” who may not have been interested in the harsh realities of cancer.

Patients within the study who developed the rare skin condition were more likely to experience better tumor responses than those who did not develop the side effect.

Watch Dr. Vitaly Margulis, from UT Southwestern Medical Center, discuss staging, during the CURE Educated Patient Kidney Cancer Summit.

Patients with myeloproliferative neoplasms, a group of blood cancers, who plan to conceive should talk with their doctor about their obstetric and medical history and risk of complications, according to an expert.

An expert discusses the resources and support available to people to better face their end-of-life journey.

A trauma therapist who specializes in cancer would have been helpful for my wife and I as we navigated her cancer experience, but the option was never discussed at our health care visits.

Activating mutations in this class of oncogenes, specifically KRAS, have made a big step forward scientifically and clinically just in the last couple of years.

The plan to launch the phase 1 trial to evaluate the safety and efficacy of combining the CAR-T cell therapy and oncolytic virus in patients with recurrent glioblastoma, a type of brain cancer, is supported by interim data from two ongoing trials.

Recent advancements surrounding the development of biomarker- targeted therapies have revolutionized the treatment of lung cancer.

The plan, according to the San Diego-based pharmaceutical company, is to launch a phase 3 trial to analyze the safety and efficacy of a novel drug in mantle cell lymphoma in the second half of 2022.

The primary focus of the trial is to evaluate the incidence of treatment-emergent and serious side effects in patients receiving either the novel drug alone or in combination with Keytruda.

When I was first diagnosed with metastatic breast cancer, I did not know there were so many other people like me until I attended Living Beyond Breast Cancer’s Conference on Metastatic Breast Cancer.

From a Netflix star revealing a breast cancer diagnosis to “Good Morning America” host Robin Roberts sharing what emotions she felt when partner Amber Laign was diagnosed with breast cancer, here’s what is happening in the cancer space this week.

Compared with Yervoy alone, the use of Yervoy plus Opdivo was associated with a significant survival benefit as a second-line treatment in patients with previously treated advanced melanoma, a type of skin cancer.

Patients who are part of an advocacy group may be better equipped to understand biomarker testing during a lung cancer diagnosis and feel more empowered.

Early 2022 was difficult for me, with the death of my dog and some difficult cancer-related situations, but thankfully, I know wonderful people who helped pull me out of my slump.

Over the past 20 years, advancements in the lung cancer space have led to a drastic paradigm shift in how patients are now treated, ultimately leading to substantial improvements in survival and patient quality of life.

The Food and Drug Administration granted a fast-track designation to Bria-IMT for the treatment of patients with metastatic breast cancer.

Investigators plan to enroll approximately 90 patients with squamous cell carcinoma of the head and neck, as well as metastatic bladder and non-small cell lung cancer.

The FDA’s recent approval of Opdivo plus chemotherapy may be beneficial for some patients with non-small cell lung cancer, further highlighting the need for multidisciplinary care.

After surviving cancer, I’ve developed complex post-traumatic stress disorder, which comes with feelings of insecurity and anger.

Anti-TIGIT immunotherapy drugs may improve quality of life and survival, while being well tolerated by patients.

In recent years, BCMA-targeted therapies have changed the landscape of relapsed/refractory myeloma treatment, filling a previously unmet need.

The FDA’s partial hold means that no new patients with either leukemia or lymphoma can be enrolled onto the trial.

Anemia and anticoagulant use were both associated with higher blood loss and drainage volume, which may prolong a hospital stay after breast reconstruction surgery, according to recent study results.

As I prepared for my friend’s celebration of life, I reflected on other loved ones I lost to cancer and pondered why I am lucky enough to survive.

The KRAS G12C gene mutation in non-small cell lung cancer has been deemed “undruggable,” but recent effective therapies have successfully targeted this mutation, leading to shrinking of tumors and longer survival.